Evidence map›Paper›PMID 25747405›Full record

Observational studyThe American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry2015

Donepezil treatment in ethnically diverse patients with Alzheimer disease.

Jared R Tinklenberg, Helena C Kraemer, Kristine Yaffe, Ruth O'Hara, John M Ringman, John W Ashford, Jerome A Yesavage, Joy L Taylor, California Alzheimer's Disease Centers

Open access · hybridAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Jared R TinklenbergSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA. Electronic address: jerytink@stanford.edu.
Helena C KraemerSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
Kristine YaffeDepartment of Psychiatry, University of California, San Francisco, CA; Sierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs San Francisco Health Care System, San Francisco, CA.
Ruth O'HaraSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
John M RingmanMary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California Los Angeles, Los Angeles CA.
John W AshfordSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
Jerome A YesavageSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
Joy L TaylorSierra Pacific Mental Illness, Research, Education and Clinical Center, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA; Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford, CA.
California Alzheimer's Disease Centers
Stanford University · USVA Palo Alto Health Care System · USUniversity of California, Los Angeles · USUniversity of California, San Francisco · US

Funding

STANFORD ALZHEIMER'S DISEASE CORE CENTERP30AG017824 · NIA · STANFORD UNIVERSITY · PI YESAVAGE, JEROME A · 2000 to 2005
$5.3M
RELIGION, AGING, AND ADAPTATION TO OPEN-HEART SURGERYR01AG016750 · NIA · RUTGERS THE ST UNIV OF NJ NEW BRUNSWICK · PI CONTRADA, RICHARD J · 2000 to 2003
$1.5M
NIA NIH HHS AG016750NIA NIH HHS AG17824NIA NIH HHS P30 AG017824NIA NIH HHS R01 AG016750
6 · The paper itself

Abstract

objectiveTo compare the outcome of donepezil treatment in ethnically diverse Alzheimer disease (AD) patients with ethnically diverse AD patients who did not receive donepezil.

methodsPatients meeting NINCDS-ADRA criteria for probable or possible AD from a consortium of California sites were systematically followed for at least 1 year in this prospective, observational study. Their treatment regimens, including prescription of donepezil, were determined by their individual physician according to his or her usual criteria. Patients self-identified their ethnicity.

resultsThe 64 ethnically diverse AD patients who completed the study and received donepezil treatment had an average 1-year decline of 2.30 points (standard deviation: 3.9) on the 30-point Mini-Mental State Exam compared with a 1.70-point (standard deviation: 4.2) decline in the 74 ethnically diverse completers who received no donepezil or other anti-AD drugs during the study period. This difference was not statistically significant. The overall Cohen effect size of this treatment-associated difference was estimated at -0.15. After using propensity analyses and other techniques to assess factors that could bias prescribing decisions, the lack of benefits associated with donepezil treatment remained. The lack of donepezil benefits also remained when more traditional analyses were applied to these data.

conclusionEthnically diverse AD patients in this study apparently did not benefit from 1 year of donepezil treatment. These unpromising results are in contrast to modest benefits of donepezil treatment measured in a directly comparable California study involving white non-Latino AD patients.

Indexed as

AgedAlzheimer DiseaseDonepezilEthnicityFemaleHumansIndansMaleNootropic AgentsPiperidinesProspective StudiesTreatment OutcomeDonepezilIndansNootropic AgentsPiperidinesAlzheimer diseaseclinical practiceDonepezil effectivenessethnic diversityobservational studiespropensity analyses

Identifiers

PMID25747405
PMCPMC4874327
OpenAlexW2073888790

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.